Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 7/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9905722 | 0.86 | HSPB1 (0.49) | MAPTPKMMEN1KMT2AHSP90AA1 | |
| SCHEMBL30193740 | 0.86 | HSPB1 (0.49) | MAPTPKMMEN1KMT2AHSP90AA1 | |
| SCHEMBL30794363 | 0.82 | KEAP1 (0.33) | L3MBTL1 | |
| SCHEMBL9901095 | 0.82 | KEAP1 (0.33) | L3MBTL1 | |
| SCHEMBL25027842 | 0.81 | ALDH1A1 (0.38) | MAPTPKMMEN1KMT2ARAB9A | |
| SCHEMBL30193800 | 0.81 | ALDH1A1 (0.38) | MAPTPKMMEN1KMT2ARAB9A | |
| SCHEMBL9901302 | 0.81 | HSPB1 (0.44) | MAPTMEN1KMT2ARAB9ALMNA | |
| SCHEMBL9900414 | 0.81 | MEN1 (0.35) | MAPTPKMMEN1KMT2ARAB9A | |
| SCHEMBL15303377 | 0.81 | MAPT (0.36) | MAPTPKMMEN1KMT2AHSP90AA1 | |
| SCHEMBL22712642 | 0.80 | MAPT (0.38) | MAPTPKMMEN1KMT2AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-20200360379-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2020-11-19 | — | — | US | disclosed |
| US-20200360379-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2020-11-19 | — | — | US | disclosed |
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2019-06-27 | — | — | US | disclosed |
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2019-06-27 | — | — | US | disclosed |
| US-9346790-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| US-9346790-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| EP-2649066-B1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | disclosed |
| EP-2649066-B1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | disclosed |
| EP-2649066-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | MAPT 3926/4885PKM 438/4885MEN1 1596/4885 |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | MAPT 3926/4885PKM 438/4885MEN1 1596/4885 |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | MAPT 3926/4885PKM 438/4885MEN1 1596/4885 |
| US-20200360379-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | MAPT 3926/4885PKM 438/4885MEN1 1596/4885 |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | MAPT 3971/4885PKM 394/4885MEN1 1367/4885 |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | MAPT 3926/4885PKM 438/4885MEN1 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.